JP5341749B2 - 脂肪肝又は非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬 - Google Patents
脂肪肝又は非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬 Download PDFInfo
- Publication number
- JP5341749B2 JP5341749B2 JP2009508889A JP2009508889A JP5341749B2 JP 5341749 B2 JP5341749 B2 JP 5341749B2 JP 2009508889 A JP2009508889 A JP 2009508889A JP 2009508889 A JP2009508889 A JP 2009508889A JP 5341749 B2 JP5341749 B2 JP 5341749B2
- Authority
- JP
- Japan
- Prior art keywords
- fatty liver
- prevention
- treatment
- liver
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims description 28
- 208000004930 Fatty Liver Diseases 0.000 title claims description 22
- 206010019708 Hepatic steatosis Diseases 0.000 title claims description 22
- 208000010706 fatty liver disease Diseases 0.000 title claims description 21
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims description 21
- 230000002265 prevention Effects 0.000 title claims description 15
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title description 16
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title description 16
- UUBHZHZSIKRVIV-KCXSXWJSSA-N (2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O UUBHZHZSIKRVIV-KCXSXWJSSA-N 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 125000001185 polyprenyl group Polymers 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 14
- 229920001550 polyprenyl Polymers 0.000 description 11
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229940125753 fibrate Drugs 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 208000027700 hepatic dysfunction Diseases 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000004291 polyenes Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000003702 retinoic acid receptors Human genes 0.000 description 2
- 108090000064 retinoic acid receptors Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- -1 cyclic retinoid Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 108091010987 retinoic acid binding proteins Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
しかしながら、ポリプレニル系化合物が脂肪肝又は非アルコール性脂肪性肝炎の予防効果及び治療効果を有することは全く知られていない。
Gastroenterology.,116, pp.1413-1419(1999) Ann. N.Y. Acad. Sci., 386, pp.111-135(1982) Atherosclerosis.,92, pp.31-40(1992) N. Eng.J. Med., 334, pp.1561-1567 (1996)
[1]脂肪肝又は非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬であって、ポリプレニル系化合物を有効成分として含む医薬。
[2]ポリプレニル系化合物がポリプレニルカルボン酸であることを特徴とする[1]に記載の医薬。
[3]ポリプレニル系化合物が3,7,11,15-テトラメチル-2,4,6,10,14-ヘキサデカペンタエン酸であることを特徴とする[1]に記載の医薬。
[5]薬学的に許容され得る製剤担体を含む医薬組成物の形態の[1]ないし[4]のいずれかに記載の医薬。
[6]経口投与製剤である[1]ないし[5]のいずれかに記載の医薬。
[7]上記の医薬の製造のためのポリプレニル系化合物の使用。
[8]脂肪肝又は非アルコール性脂肪性肝炎の予防及び/又は治療方法であって、予防及び/又は治療有効量のポリプレニル系化合物をヒトを含む哺乳類動物に投与する工程を含む方法。
本発明で使用されるポリプレニル系化合物は、公知の方法(日本国公告特許公報昭63-32058号、J. Chem. Soc.(C) 2154頁 1966年 )により合成することができる。
例1:NIK−333の肝臓中脂質量減少に関する評価
実験には、6週齢のSD系雄性ラット(日本チャールス・リバー)を用い、高脂肪食負荷群はHFD32(日本クレア)を、正常対照群はCE-2(日本クレア)を用いて、両群共に制限給餌にて1日あたり25±3gとした。表1に各飼料成分を示す。NIK−333は高脂肪食負荷開始と同時に1日1回8週間連続強制経口投与を行った。試験終了後肝臓を摘出し、肝臓中トリグリセリド(H-TG)及びコレステロール(H-T-chol)量について測定した。その結果を図1に示す。摘出した肝臓からヘマトキシリン・エオジン(H.E.)及びオイルレッドO(O.R.)染色標本を作製し病理組織学的検討を行った。H.E.染色標本から肝臓の脂肪変性の程度を5段階にグレード分けしスコア化した。また、O.R.染色標本から画像解析装置による肝臓標本面積あたりのO.R.陽性面積について算出した。それらの結果を図2に示す。さらに血清中トリグリセリド(S-TG)、総コレステロール(S-T-chol)、アラニンアミノトランスフェラーゼ(S-ALT)、アスパラギン酸アミノトランスフェラーゼ(S-AST)について測定した。その結果を図3、図4に示す。
7週齢のC57BL/6Nマウス(日本チャールス・リバー)にNIK−333またはATRAをそれぞれ1日1回2週間連続強制経口投与した。試験終了後、各個体のS-TG濃度及び精巣重量を測定した。それぞれの結果を図5及び図6に示す。なお、対照群にはダイズ油を投与した。
以上の結果から、本発明は、脂肪肝又は非アルコール性脂肪性肝炎の予防及び/又は治療に用いる新しい医薬として有用であるということができる。
Claims (4)
- 脂肪肝の予防及び/又は治療のための医薬であって、3,7,11,15-テトラメチル-2,4,6,10,14-ヘキサデカペンタエン酸を有効成分として含む医薬。
- (2E,4E,6E,10E)-3,7,11,15-テトラメチル-2,4,6,10,14-ヘキサデカペンタエン酸を有効成分として含む請求項1に記載の医薬。
- 薬学的に許容され得る製剤担体を含む医薬組成物の形態である請求項1又は2に記載の医薬。
- 経口投与製剤である請求項1ないし3のいずれか1項に記載の医薬。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009508889A JP5341749B2 (ja) | 2007-03-30 | 2008-03-27 | 脂肪肝又は非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007090114 | 2007-03-30 | ||
JP2007090114 | 2007-03-30 | ||
JP2009508889A JP5341749B2 (ja) | 2007-03-30 | 2008-03-27 | 脂肪肝又は非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬 |
PCT/JP2008/000760 WO2008126363A1 (ja) | 2007-03-30 | 2008-03-27 | 脂肪肝又は非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013132957A Division JP2013216679A (ja) | 2007-03-30 | 2013-06-25 | 非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2008126363A1 JPWO2008126363A1 (ja) | 2010-07-22 |
JP5341749B2 true JP5341749B2 (ja) | 2013-11-13 |
Family
ID=39863523
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009508889A Expired - Fee Related JP5341749B2 (ja) | 2007-03-30 | 2008-03-27 | 脂肪肝又は非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬 |
JP2013132957A Pending JP2013216679A (ja) | 2007-03-30 | 2013-06-25 | 非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013132957A Pending JP2013216679A (ja) | 2007-03-30 | 2013-06-25 | 非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20100120914A1 (ja) |
EP (1) | EP2143430B1 (ja) |
JP (2) | JP5341749B2 (ja) |
KR (1) | KR101461252B1 (ja) |
CN (1) | CN101652134B (ja) |
ES (1) | ES2555782T3 (ja) |
HK (1) | HK1138200A1 (ja) |
WO (1) | WO2008126363A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5725491B2 (ja) * | 2010-04-14 | 2015-05-27 | 国立大学法人鳥取大学 | レチノイン酸受容体リガンドによるインスリン抵抗性改善作用 |
JP5304939B1 (ja) * | 2012-05-31 | 2013-10-02 | 大日本印刷株式会社 | 光学積層体、偏光板、偏光板の製造方法、画像表示装置、画像表示装置の製造方法及び画像表示装置の視認性改善方法 |
GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
EP2808031A1 (en) * | 2013-05-30 | 2014-12-03 | Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca | Sex hormone-binding globulin for use as a medicament |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04290821A (ja) * | 1990-12-07 | 1992-10-15 | Efamol Ltd | 液体栄養副作用の予防方法またはそれに用いる薬剤の製造方法 |
JPH09194362A (ja) * | 1996-01-19 | 1997-07-29 | Bizen Kasei Kk | ドコサヘキサエン酸及びエイコサペンタエン酸含有リン脂質を含む組成物 |
WO2001080854A1 (fr) * | 2000-04-24 | 2001-11-01 | Nikken Chemicals Co., Ltd. | Activateurs destines au recepteur active par le proliferateur de peroxisomes |
JP2002104965A (ja) * | 2000-09-27 | 2002-04-10 | Kanegafuchi Chem Ind Co Ltd | 脂肪肝予防・改善機能を有する組成物 |
WO2003097034A1 (fr) * | 2002-05-17 | 2003-11-27 | Nikken Chemicals Co., Ltd. | Inhibiteurs de l'expression du tgf-$g(a) |
WO2005079783A1 (ja) * | 2004-02-25 | 2005-09-01 | The University Of Tokyo | 転写因子klf5の活性化抑制作用を有する医薬 |
JP2006232711A (ja) * | 2005-02-24 | 2006-09-07 | Tohoku Univ | 血中中性脂肪低下作用および肝臓中性脂肪合成抑制作用および血小板凝集抑制作用を有する油脂 |
JP2007314492A (ja) * | 2006-05-29 | 2007-12-06 | National Agriculture & Food Research Organization | 脂質代謝改善用組成物 |
JP2008150307A (ja) * | 2006-12-15 | 2008-07-03 | Kenko Tsusho Kk | 体脂肪の蓄積に起因する疾患の治療剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56140949A (en) * | 1980-04-07 | 1981-11-04 | Eisai Co Ltd | 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenic acid |
JPS57106638A (en) | 1980-12-24 | 1982-07-02 | Eisai Co Ltd | Conjugated polyprenylcarboxylic acid and its derivative |
JPS6332058A (ja) | 1986-07-22 | 1988-02-10 | 株式会社 梅彦 | 石材の床張り方法 |
US5922345A (en) * | 1990-12-07 | 1999-07-13 | Scotia Holdings Plc | Nutrition |
JP2004290821A (ja) | 2003-03-27 | 2004-10-21 | Aichi Electric Co Ltd | 混合装置 |
-
2008
- 2008-03-27 CN CN200880011149.2A patent/CN101652134B/zh not_active Expired - Fee Related
- 2008-03-27 KR KR1020097022514A patent/KR101461252B1/ko not_active IP Right Cessation
- 2008-03-27 US US12/593,053 patent/US20100120914A1/en not_active Abandoned
- 2008-03-27 ES ES08720639.7T patent/ES2555782T3/es active Active
- 2008-03-27 WO PCT/JP2008/000760 patent/WO2008126363A1/ja active Application Filing
- 2008-03-27 JP JP2009508889A patent/JP5341749B2/ja not_active Expired - Fee Related
- 2008-03-27 EP EP08720639.7A patent/EP2143430B1/en not_active Not-in-force
-
2010
- 2010-05-03 HK HK10104346.1A patent/HK1138200A1/xx not_active IP Right Cessation
-
2012
- 2012-06-15 US US13/524,134 patent/US8673976B2/en not_active Expired - Fee Related
-
2013
- 2013-06-25 JP JP2013132957A patent/JP2013216679A/ja active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04290821A (ja) * | 1990-12-07 | 1992-10-15 | Efamol Ltd | 液体栄養副作用の予防方法またはそれに用いる薬剤の製造方法 |
JPH09194362A (ja) * | 1996-01-19 | 1997-07-29 | Bizen Kasei Kk | ドコサヘキサエン酸及びエイコサペンタエン酸含有リン脂質を含む組成物 |
WO2001080854A1 (fr) * | 2000-04-24 | 2001-11-01 | Nikken Chemicals Co., Ltd. | Activateurs destines au recepteur active par le proliferateur de peroxisomes |
JP2002104965A (ja) * | 2000-09-27 | 2002-04-10 | Kanegafuchi Chem Ind Co Ltd | 脂肪肝予防・改善機能を有する組成物 |
WO2003097034A1 (fr) * | 2002-05-17 | 2003-11-27 | Nikken Chemicals Co., Ltd. | Inhibiteurs de l'expression du tgf-$g(a) |
WO2005079783A1 (ja) * | 2004-02-25 | 2005-09-01 | The University Of Tokyo | 転写因子klf5の活性化抑制作用を有する医薬 |
JP2006232711A (ja) * | 2005-02-24 | 2006-09-07 | Tohoku Univ | 血中中性脂肪低下作用および肝臓中性脂肪合成抑制作用および血小板凝集抑制作用を有する油脂 |
JP2007314492A (ja) * | 2006-05-29 | 2007-12-06 | National Agriculture & Food Research Organization | 脂質代謝改善用組成物 |
JP2008150307A (ja) * | 2006-12-15 | 2008-07-03 | Kenko Tsusho Kk | 体脂肪の蓄積に起因する疾患の治療剤 |
Non-Patent Citations (4)
Title |
---|
JPN6008021171; 田中智洋 他, 脂肪肝におけるPPARsの臨床的意義 , 日本臨床, 2005, Vol.63, No.4, p.700-706 * |
JPN6008021177; TAKEDA,N. et al, KLF5 inhibitor Am80 reduces atherosclerosis, adipose tissue growth, and fatty liver * |
JPN6013013060; MUTO,Y. et al: 'Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepat' N Engl J Med Vol.334, No.24, 1996, p.1561-7 * |
JPN7008003878; FACTOR,V.M. et al, Disruption of redox homeostasis in the transforming growth factor-alpha/c-myc tra * |
Also Published As
Publication number | Publication date |
---|---|
CN101652134B (zh) | 2015-07-15 |
US20100120914A1 (en) | 2010-05-13 |
EP2143430A4 (en) | 2010-12-29 |
US20120259015A1 (en) | 2012-10-11 |
EP2143430A1 (en) | 2010-01-13 |
US8673976B2 (en) | 2014-03-18 |
ES2555782T3 (es) | 2016-01-08 |
HK1138200A1 (en) | 2010-08-20 |
JPWO2008126363A1 (ja) | 2010-07-22 |
JP2013216679A (ja) | 2013-10-24 |
EP2143430B1 (en) | 2015-09-23 |
KR20100015986A (ko) | 2010-02-12 |
WO2008126363A1 (ja) | 2008-10-23 |
KR101461252B1 (ko) | 2014-11-12 |
CN101652134A (zh) | 2010-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11141399B2 (en) | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis | |
US20220175709A1 (en) | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same | |
US20140186438A1 (en) | Compositions comprising epa and obeticholic acid and methods of use thereof | |
US8017652B2 (en) | Activators of peroxisome proliferator-activated receptors | |
WO2010038796A1 (ja) | C型肝炎治療剤 | |
US8461141B2 (en) | Preventive or therapeutic drug for Alzheimer-type dementia | |
KR20170020514A (ko) | 중증 고중성지방혈증의 치료 | |
JP5341749B2 (ja) | 脂肪肝又は非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬 | |
US20190030005A1 (en) | Therapeutic agent for dyslipidemia | |
Kanuri et al. | Effect of moderate alcohol consumption on the development of non-alcoholic fatty liver disease (NAFLD) in ob/ob mice: 1452 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130214 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130326 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130625 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130709 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130806 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130808 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5341749 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |